Evidence map›Paper›PMID 42393435›Full record

ReviewCalcified tissue international2026

Cytokine Networks Reprogramming the Osteo-Immune Microenvironment in Cancer Bone Metastasis.

Toru Hiraga

Abstract readReview
PubMed Publisher
In one paragraph

Review in Calcified tissue international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Toru HiragaDepartment of Histology and Cell Biology, Matsumoto Dental University, 1780 Gobara-Hirooka, Shiojiri, Nagano, 399-0781, Japan. toru.hiraga@mdu.ac.jp.ORCID http://orcid.org/0000-0002-7829-2395

Funding

JSPS KAKENHI JP21K09863JSPS KAKENHI JP24K12891
6 · The paper itself

Abstract

Bone metastasis is a major clinical challenge and is frequently associated with resistance to immunotherapy and progressive skeletal destruction. Although cytokines are recognized as key regulators of both immune responses and bone remodeling, their integrated roles in the bone metastatic niche remain incompletely understood. Here, we propose a conceptual framework in which cytokine-driven osteo-immune reprogramming shapes the bone microenvironment into a state that supports tumor persistence. Within this framework, cytokines can be categorized into three functional groups-immune-dominant mediators, osteo-immune regulators, and divergent factors-whose context-dependent activities collectively coordinate immune suppression and osteoclastic bone destruction. Rather than acting independently, these cytokines form interconnected networks that establish reinforcing interactions, thereby stabilizing an immunologically cold and therapy-resistant niche. This integrated perspective suggests that immune resistance in bone metastasis does not arise solely from tumor-intrinsic properties, but emerges from dynamic crosstalk in the osteo-immune axis. The spatiotemporal regulation of cytokine signaling likely defines stage-specific vulnerabilities, providing opportunities for therapeutic intervention. Targeting cytokine networks in combination with immune checkpoint inhibitors and bone-modifying agents may represent a rational strategy to disrupt pathogenic osteo-immune circuits. A deeper understanding of the reprogramming of the bone microenvironment by cytokines will be essential for enabling durable immunotherapeutic responses in patients with bone metastatic disease.

Indexed as

Bone NeoplasmsCytokinesTumor MicroenvironmentAnimalsHumansImmunotherapySignal TransductionCytokinesBone metastasisCytokinesImmune microenvironmentImmunotherapyOsteoclastsOsteoimmunology

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.